Upcoming Webinar: Computation in Drug Discovery — An Insider’s View
Computation in Drug Discovery — An Insider's View
December 1, 2022 • 8:00AM (PT), 11:00AM (ET), 16:00 (GMT)
Computational and data-driven drug discovery approaches are promising to revolutionize the biopharmaceutical industry. On a practical level, however, research teams need to overcome a number of challenges to truly harness the power of data and turn it into discoveries.
In this webinar, we've invited two industry veterans, Drs. Josh Horan (Nuvalent) and Michael Kappler (IDEAYA Biosciences), to share their first-hand experience working with data at leading biotech companies. We will go beyond the hype of AI/machine learning and dive into the nuts and bolts of building computational drug discovery capabilities from the ground up.
Featuring these leading scientists...
Eric Gifford, PhD
Customer Success Scientist,
Collaborative Drug Discovery
Eric Gifford is a Customer Success Scientist at Collaborative Drug Discovery. Prior to joining CDD, he had a long tenure with multinational pharmaceutical companies Merck and Pfizer where he lead many informatics projects.
Joshua Horan, PhD
VP - Medicinal Chemistry,
Joshua Horan is the Vice President of Medicinal Chemistry at Nuvalent Inc, a biotech company creating precisely targeted therapies for patients with cancer. Previously Dr. Horan worked at Proteostasis Therapeutics, working in phenotypic drug discovery. He started his career at Boehringer Ingelheim working on small molecule drug discovery in inflammation and immunology.
Michael Kappler, PhD
Director, Head of Research Infomatics,
Michael Kappler joined IDEAYA Biosciences, a synthetic lethality-focused precision medicine oncology company, in 2020 to lead its Research Informatics team. Prior to joining IDEAYA, he worked at Nurix, Roche, Amgen, Daylight, and founded Moonlight Informatics & Computing Knowledge LLC.